- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Howard Burris Discusses Simultaneous Approvals of Novel Therapies, Diagnostics
With a biomarker attached, the odds of a drug being approved goes up from about 10% to greater than 25%, explained Howard A. "Skip" Burris, III, MD, FACP, FASCO, president, clinical operations, and chief medical officer of Sarah Cannon Research Institute.
With a biomarker attached, the odds of a drug being approved goes up from about 10% to greater than 25%, explained Howard A. "Skip" Burris, III, MD, FACP, FASCO, president, clinical operations, and chief medical officer of Sarah Cannon Research Institute.
Transcript
When the FDA approved atezolizumab for the treatment of triple-negative breast cancer, it also approved the VENTANA PD-L1 assay. Do you think simultaneous approvals like this will be a trend in the future?
I do think that we’re going to see more and more of the development of the biomarker along with the individual cancer therapy. There’s some data that’s been published recently that has been talked about that shows that if a biomarker is part of your clinical development strategy, you have a much greater chance of approval. We know that many drugs come out of the phase 1 setting and don’t make it through the whole approval process, but with a biomarker attached, the odds of that drug being approved go up from about 10% to greater than 25%. So, identifying the patients that are most likely to benefit, I think, will be key, and it’s nice to see the FDA working with pharma to in fact promote this kind of strategy.
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Dr Michael Farwell on FDG PET/CT Imaging to Predict Immunotherapy Response in Advanced Melanoma
April 15th 2024Michael Farwell, MD, associate professor of radiology at the Hospital of the University of Pennsylvania, provides insights into a study on the benefits of using 18F-fluorodeoxyglucose (FDG) PET/CT imaging to detect metabolic tumor changes in skin cancer.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Increasing Lp(a) Awareness for Better Cardiovascular Health: Dr Mary McGowan
March 24th 2024For Lp(a) Awareness Day, Mary McGowan, MD, FNLA, chief medical officer of the Family Heart Foundation, highlights how most people with elevated Lp(a) are completely unaware that they have this increased risk and calls for increased testing.
Read More
Dr Al Benson on Reimbursement for Supportive Care When Treating Patients With Cancer
March 22nd 2024Al Benson, MD, FACP, FACCC, FASCO, medical oncologist at Northwestern University Feinberg School of Medicine and associate director of the Robert E. Tillery Comprehensive Cancer Center, discussed findings from a national survey assessing barriers to comprehensive cancer care delivery.
Read More
